MOTS-c: what the published research shows
MOTS-c is a mitochondrial-encoded peptide studied in host defense, metabolic and cardiovascular models. Here is what the published literature reports, and where the evidence is animal-only or in vitro.
MOTS-c — mitochondrial open reading frame of the 12S rRNA type-c, also written mitochondrial open-reading frame of the 12S rRNA-c — is a mitochondrial-derived peptide (MDP) and mitokine encoded within the 12S rRNA region of mitochondrial DNA. Published work describes it as an amphipathic and cationic host defense peptide (HDP) with direct antibacterial and immunomodulatory functions, consistent with the peptide chemistry of known HDPs [1]. The wild-type sequence is given in the literature as Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg, with a hydrophobicity index of -0.938 [4]. The evidence block does not supply a molecular formula or molecular weight, so none is stated here. MOTS-c is supplied for laboratory research use only.
The work centres on mitochondrial bioenergetics and stress-responsive signalling, with the NLRP3 inflammasome, Nrf2 activation, LAT1-mediated uptake and mitochondrial genome integrity recurring as the mechanistic nodes in the studies below [2][4][12].
Research Studies
MOTS-c and host defense peptide activity
A study identified MOTS-c as a host defense peptide encoded in the human mitochondrial genome, presumably derived from primordial proto-mitochondrial bacteria. The peptide was reported to be amphipathic and cationic, with direct antibacterial and immunomodulatory functions, and it targeted Escherichia coli in the reported assays [1]. This positions MOTS-c within a framework in which the immune system is not exclusively nuclear-encoded, and in which mtDNA contributes active immune factors rather than only triggering responses or entrapping pathogens [1].
MOTS-c and NLRP3 inflammasome activity in a diabetic rat model
In a high-fat diet and streptozotocin-induced type 2 diabetes mellitus rat model, MOTS-c treatment significantly reduced fasting blood glucose and circulating C-reactive protein levels while selectively modulating plasma inflammatory mediators. The study examined leucine-rich repeat and pyrin domain-containing receptor 3 (NLRP3) inflammasome activity in the context of systemic and cardiac inflammation, which contributes to diabetic cardiomyopathy [2]. These findings are animal-only.
MOTS-c and LAT1-mediated delivery in radiation-induced lung injury
Because wild-type MOTS-c is highly polar and shows poor membrane permeability, an engineered analogue, R13A-MOTS-c, was generated by substituting the polar arginine at position 13 with alanine. This raised the hydrophobicity index from -0.938 to -0.544 and measurably improved cellular uptake. Competition assays with canonical LAT1 substrates (leucine, BCH) and LAT1 knockdown experiments confirmed that R13A-MOTS-c enters cells via LAT1-mediated transport. In the reported model, this delivery attenuated radiation-induced lung injury via Nrf2 activation and mitochondrial protection [4]. The uptake and mechanism data include in vitro work; the injury model is preclinical.
MOTS-c and atrial fibrillation in human tissue and mouse models
Expression of humanin and MOTS-c in human atrial tissues was analysed using public GEO data, immunohistochemistry and immunofluorescence, and plasma levels were measured. In an angiotensin II-induced mouse model and primary cardiac cells, humanin and MOTS-c attenuated atrial fibrillation by suppressing fibrosis and mitochondrial dysfunction [5]. The human component is observational tissue and plasma analysis; the interventional findings are from animal and primary-cell work.
MOTS-c and myocardial ischemia-reperfusion injury in acute myocardial infarction
A cross-sectional study enrolled 72 acute myocardial infarction patients undergoing percutaneous coronary intervention and divided them into MIRI (n = 34) and non-MIRI (n = 38) groups. Clinical data and MOTS-c levels were measured in peripheral serum and intracoronary samples to examine the relationship between serum MOTS-c and myocardial ischemia-reperfusion injury [6]. This is an association study in patients; it does not establish that MOTS-c administration modifies MIRI.
MOTS-c and thyroid autoimmunity in Hashimoto's thyroiditis
A cross-sectional study compared 90 patients diagnosed with Hashimoto's thyroiditis against age- and sex-matched healthy controls, testing the association between circulating MOTS-c levels and thyroid autoimmunity and metabolic regulation. Reduced circulating MOTS-c levels were reported to reflect integrated autoimmune and metabolic dysregulation [3]. The design is cross-sectional, so directionality is not established.
MOTS-c and polycystic ovary syndrome in adolescents
A study investigated differences in MOTS-c levels between adolescents diagnosed with polycystic ovary syndrome and those without, together with associations to metabolic parameters, and evaluated the relationship between the MOTS-c gene polymorphism m.1382A>C and serum MOTS-c levels in this population. The polymorphism had previously been linked to increased type 2 diabetes risk in men, and the authors note that no prior studies had explored the polymorphism and MOTS-c levels in adolescents with PCOS [7].
MOTS-c and anaesthetic technique in renal transplantation
A prospective controlled trial compares sevoflurane general anaesthesia with combined spinal-epidural anaesthesia in kidney transplant recipients, with ferroptosis, humanin and MOTS-c levels as endpoints. The rationale is that ischemia-reperfusion injury may affect graft function and long-term outcomes, and that the effects of different anaesthetic techniques on these biomarkers in this population had not been investigated [8]. This is a registered trial record; results are not reported in the evidence block.
MOTS-c and mesenchymal stromal cell reparative function
Work in human mesenchymal stromal cells reports that MOTS-c activates metabolic signalling but blunts reparative function, in a context where obesity compromises MSC metabolism and reparative capacity [10]. This is a cell-based finding and runs counter to a simple protective reading of the peptide.
MOTS-c and cardiac ischemia-reperfusion injury
A study reports that MOTS-c preserves mitochondrial subpopulation bioenergetics and genome integrity to attenuate cardiac ischemia-reperfusion injury, in a setting where mitochondrial dysfunction contributes to injury through impaired bioenergetics, oxidative stress and disrupted mitochondrial homeostasis [12]. This is preclinical mechanistic work.
Comparison of reported MOTS-c findings by model
| Model or population | Reported finding | Evidence type |
|---|---|---|
| E. coli assays | Direct antibacterial and immunomodulatory activity as a host defense peptide [1] | In vitro |
| T2DM rat model | Reduced fasting blood glucose and CRP; selective modulation of plasma inflammatory mediators; NLRP3 suppression [2] | Animal |
| Radiation-induced lung injury model | R13A-MOTS-c uptake via LAT1; attenuation via Nrf2 activation and mitochondrial protection [4] | In vitro and preclinical |
| Human atrial tissue; AngII mouse model | Attenuated atrial fibrillation by suppressing fibrosis and mitochondrial dysfunction [5] | Human tissue plus animal |
| AMI patients undergoing PCI (n = 72) | Association between serum MOTS-c and MIRI [6] | Human cross-sectional |
| Hashimoto's thyroiditis patients (n = 90) and controls | Reduced circulating MOTS-c [3] | Human cross-sectional |
| Adolescents with and without PCOS | MOTS-c levels and m.1382A>C polymorphism associations [7] | Human cross-sectional |
| Kidney transplant recipients | Ferroptosis, humanin and MOTS-c levels by anaesthetic technique [8] | Registered trial |
| Human mesenchymal stromal cells | Metabolic signalling activated; reparative function blunted [10] | In vitro |
| Cardiac ischemia-reperfusion model | Preserved mitochondrial subpopulation bioenergetics and genome integrity [12] | Preclinical |
MOTS-c in sepsis-induced cardiomyopathy and inflammatory lung disease
Review material describes MOTS-c as a mitochondrial-derived microprotein with intracrine, paracrine and endocrine effects across multiple tissues, initially described as a regulator of metabolic homeostasis and now also discussed as a modulator of oxidative and inflammatory processes in inflammatory lung disease [11]. A separate review addresses mechanisms and translational potential in sepsis-induced cardiomyopathy, a complication characterised by inflammatory dysregulation, mitochondrial dysfunction, metabolic disturbance and changes in the myocardial microenvironment [9]. Both are review-level sources and are cited here as background rather than as primary findings.
If you are reading this for personal health reasons
MOTS-c is sold by our catalogue strictly for laboratory research use, and we do not provide dosing information or medical guidance of any kind. Nothing on this page is a recommendation for human use, and the studies cited are largely preclinical, cross-sectional or in vitro. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] https://europepmc.org/article/PMC/PMC13485304
- [2] https://europepmc.org/article/PMC/PMC13394035
- [3] https://europepmc.org/article/PMC/PMC13257931
- [4] https://europepmc.org/article/PMC/PMC13199819
- [5] https://europepmc.org/article/PMC/PMC13204372
- [6] https://europepmc.org/article/PMC/PMC13113351
- [7] https://europepmc.org/article/PMC/PMC13055642
- [8] https://clinicaltrials.gov/study/NCT07678073
- [9] https://pubmed.ncbi.nlm.nih.gov/42633878/
- [10] https://europepmc.org/article/PMC/PMC13536784
- [11] https://europepmc.org/article/PMC/PMC13466091
- [12] https://pubmed.ncbi.nlm.nih.gov/42228044/